Junwen Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Junwen Deng has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Shawn G. Kwatra
Department of Dermatology, University of Maryland School of Medicine, Baltimore, USA
10 shared publications - Varsha Parthasarathy
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD
9 shared publications - Zachary A. Bordeaux
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
7 shared publications - Madan M. Kwatra
Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina, USA
6 shared publications - Matthew T. Taylor
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
6 shared publications - Martin Prince Alphonse
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland
5 shared publications
Latest Publications
- 24 March 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (11) , 2501-2512.e4
Spatial Mass Cytometry–Based Single-Cell Imaging Reveals a Disrupted Epithelial–Immune Axis in Prurigo Nodularis
- 24 March 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (11) , 2501-2512.e4
Spatial Mass Cytometry–Based Single-Cell Imaging Reveals a Disrupted Epithelial–Immune Axis in Prurigo Nodularis
- Top Cited PapersOpen Access
- 19 January 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (7) , 1568-1578.e5
Single-Cell RNA Sequencing Reveals Dysregulated POSTN+WNT5A+ Fibroblast Subclusters in Prurigo Nodularis
- 19 January 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (7) , 1568-1578.e5
Top Cited PapersOpen AccessSingle-Cell RNA Sequencing Reveals Dysregulated POSTN+WNT5A+ Fibroblast Subclusters in Prurigo Nodularis
- Open Access
- 11 December 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1335252
The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy
Despite the emergence of molecular targeted therapy and immune checkpoint inhibitors as standard first-line treatments for non-small cell lung cancer (NSCLC), their efficacy in some patients is limited by intrinsic and acquired resistance. Antibody-drug conjugates (ADCs), a revolutionary class of antitumor drugs, have displayed promising clinical outcomes in cancer treatment. In 2022, trastuzumab deruxtecan (Enhertu) was approved for treating HER2-mutated NSCLC, thereby underscoring the clinical value of ADCs in NSCLC treatment strategies. An increasing number of ADCs, focusing on NSCLC, are undergoing clinical trials, potentially positioning them as future treatment options. In this review, we encapsulate recent advancements in the clinical research of novel ADCs for treating NSCLC. Subsequently, we discuss the mechanisms of action, clinical efficacy, and associated limitations of these ADCs.
- 11 December 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1335252
Open AccessThe clinical development of antibody-drug conjugates for non-small cell lung cancer therapy
Despite the emergence of molecular targeted therapy and immune checkpoint inhibitors as standard first-line treatments for non-small cell lung cancer (NSCLC), their efficacy in some patients is limited by intrinsic and acquired resistance. Antibody-drug conjugates (ADCs), a revolutionary class of antitumor drugs, have displayed promising clinical outcomes in cancer treatment. In 2022, trastuzumab deruxtecan (Enhertu) was approved for treating HER2-mutated NSCLC, thereby underscoring the clinical value of ADCs in NSCLC treatment strategies. An increasing number of ADCs, focusing on NSCLC, are undergoing clinical trials, potentially positioning them as future treatment options. In this review, we encapsulate recent advancements in the clinical research of novel ADCs for treating NSCLC. Subsequently, we discuss the mechanisms of action, clinical efficacy, and associated limitations of these ADCs.
- 26 May 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (12) , 2416-2426.e1
A Polygenic Risk Score for Predicting Racial and Genetic Susceptibility to Prurigo Nodularis
- 26 May 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (12) , 2416-2426.e1
A Polygenic Risk Score for Predicting Racial and Genetic Susceptibility to Prurigo Nodularis
- 1 October 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (4) , 608-609
Association between prurigo nodularis and substance use disorders
- 1 October 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (4) , 608-609
Association between prurigo nodularis and substance use disorders
- Open Access
- 29 September 2022
- Published by Elsevier in JID Innovations
- Vol. 3 (1) , 100107
Construction of a Secondary Enclosure for UVB Irradiation of Mice
- 29 September 2022
- Published by Elsevier in JID Innovations
- Vol. 3 (1) , 100107
Open AccessConstruction of a Secondary Enclosure for UVB Irradiation of Mice
- 20 May 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 2896-2908.e4
Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study
- 20 May 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (11) , 2896-2908.e4
Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study
- 14 March 2022
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (2) , 223-229
A cross-sectional analysis of trends in dermatology practice size in the United States from 2012 to 2020
Physicians are trending towards practice consolidation nationally; however, changes in dermatology practice size remain to be assessed. The objective of this study was to analyze trends in dermatology practice size from 2012 to 2020 using a large-scale Medicare physician database. We performed a retrospective cross-sectional analysis using 2012 and 2020 data obtained from the Physician Compare Database. Responses from dermatologists were analyzed for trends in practice size, with a sub-analysis to examine differences among different regions, gender, and years of experience. The proportion of dermatologists in solo practice decreased from 26.1% in 2012 to 15.6% in 2020 (p < 0.001). Dermatologists were 40% less likely to be practicing in solo practice and 36% more likely to be in a practice with 10 or more members in 2020 (p < 0.001). These findings were consistent among all regions and genders examined. Additionally, in 2020, dermatologists with 30 or more years in practice were 7.5 times more likely to be in solo practice compared to dermatologists with 0–9 years in practice (p < 0.001). There is a trend of dermatologists working for larger practices, which is consistent with a larger nationwide trend of expanding physician practices. This shift in practice settings should be closely monitored to analyze the effect on healthcare efficiency, cost, and delivery.
- 14 March 2022
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (2) , 223-229
A cross-sectional analysis of trends in dermatology practice size in the United States from 2012 to 2020
Physicians are trending towards practice consolidation nationally; however, changes in dermatology practice size remain to be assessed. The objective of this study was to analyze trends in dermatology practice size from 2012 to 2020 using a large-scale Medicare physician database. We performed a retrospective cross-sectional analysis using 2012 and 2020 data obtained from the Physician Compare Database. Responses from dermatologists were analyzed for trends in practice size, with a sub-analysis to examine differences among different regions, gender, and years of experience. The proportion of dermatologists in solo practice decreased from 26.1% in 2012 to 15.6% in 2020 (p < 0.001). Dermatologists were 40% less likely to be practicing in solo practice and 36% more likely to be in a practice with 10 or more members in 2020 (p < 0.001). These findings were consistent among all regions and genders examined. Additionally, in 2020, dermatologists with 30 or more years in practice were 7.5 times more likely to be in solo practice compared to dermatologists with 0–9 years in practice (p < 0.001). There is a trend of dermatologists working for larger practices, which is consistent with a larger nationwide trend of expanding physician practices. This shift in practice settings should be closely monitored to analyze the effect on healthcare efficiency, cost, and delivery.
- 4 March 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (9) , 2537-2540
Cutaneous Transcriptomics Identifies Fibroproliferative and Neurovascular Gene Dysregulation in Prurigo Nodularis Compared with Psoriasis and Atopic Dermatitis
- 4 March 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 142 (9) , 2537-2540
Cutaneous Transcriptomics Identifies Fibroproliferative and Neurovascular Gene Dysregulation in Prurigo Nodularis Compared with Psoriasis and Atopic Dermatitis
- 20 December 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 186 (5) , 903-905
Latent class analysis identification of prurigo nodularis comorbidity phenotypes
- 20 December 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 186 (5) , 903-905
Latent class analysis identification of prurigo nodularis comorbidity phenotypes